Topical local anaesthetic (tetracaine) reduces pain from botulinum toxin injections for axillary hyperhidrosis

O’Riordan, J M; Fitzgerald, Éilís; Gowing, Caitriona M; O’Grady, Helen; Feeley, T. M.; Tierney, Sean

doi:10.1002/bjs.5347

Cited by 18 publications

(10 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Attempts to reduce injection-related pain have included topical anesthetics (e.g. lidocaine [lignocaine] [155] or tetracaine [158] ); cryoanalgesia with ice, [159] cold air, [148] or dichlorotetrafluoroethane; [160,161] regional nerve blocks; [162][163][164][165] intravenous regional anesthesia (IVRA; Bier's block); [166,167] needle-free injection (e.g. MED-JET Ò ); [157,168] and vibration anesthesia.…”

Section: Palmar Hhmentioning

confidence: 99%

Botulinum Toxin for Hyperhidrosis

Grunfeld

Murray

Solish

2009

American Journal of Clinical Dermatology

View full text Add to dashboard Cite

Primary focal hyperhidrosis is a disorder of idiopathic excessive sweating that typically affects the axillae, palms, soles, and face. The disorder, which affects up to 2.8% of the US population, is associated with considerable physical, psychosocial, and occupational impairments. Current therapeutic strategies include topical aluminum salts, tap-water iontophoresis, oral anticholinergic agents, local surgical approaches, and sympathectomies. These treatments, however, have been limited by a relatively high incidence of adverse effects and complications. Non-surgical treatment complications are typically transient, whereas those of surgical therapies may be permanent and significant. Recently, considerable evidence suggests that botulinum toxin type A (BTX-A) injections into hyperhidrotic areas can considerably reduce focal sweating in multiple areas without major adverse effects. BTX-A has therefore shown promise as a potential replacement for more invasive treatments after topical aluminum salts have failed. This article reviews the epidemiology, diagnosis, and management of primary focal hyperhidrosis, with an emphasis on recent research evidence supporting the use of BTX-A injections for this indication.

show abstract

Section: Palmar Hhmentioning

confidence: 99%

Botulinum Toxin for Hyperhidrosis

Grunfeld

Murray

Solish

2009

American Journal of Clinical Dermatology

View full text Add to dashboard Cite

show abstract

“…Treatment with botulinum toxin (Allergan Parmaceuticals Ireland, Co. Mayo, Ireland) is as described previously 4 .…”

Section: Methodsmentioning

confidence: 99%

“…1e3 For these patients, it is a socially debilitating condition that has a severe impact on QoL 4 . Hyperhidrosis may be generalised or localised and there are variants that may affect the axilla, palms, trunk and face, with the former 3 being the most common 1 .…”

Section: Introductionmentioning

confidence: 99%

Experience with botulinum toxin therapy for axillary hyperhidrosis and comparison to modelled data for endoscopic thoracic sympathectomy – A quality of life and cost effectiveness analysis

et al. 2016

View full text Add to dashboard Cite

“…Another cost-effective form of anesthesis is vibration, which has been shown to reduce patient discomfort during botulinum injections [61]. Other clinicians have advocated for topical anesthetics such as tetracaines or lidocaine/prilocaine cream which have been shown to be effective but need to be applied 45 min prior to the procedure [62, 63]. Some studies have even shown that diluting OnabotulinumtoxinA with lidocaine instead of normal saline decreases pain without a loss of efficacy [64, 65].…”

Section: Current Therapies For Hyperhidrosismentioning

confidence: 99%

Current and Emerging Medical Therapies for Primary Hyperhidrosis

Grabell

Hebert

2016

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Hyperhidrosis is defined as the production of sweat beyond what is physiologically necessary to maintain thermal homeostasis. This disease state may (and typically does) have a significant impact on the patient’s quality of life. Medications including antiperspirants, anticholinergics, and botulinum toxin have been shown to be effective in the management of hyperhidrosis. Several medical device technologies have also proven to be effective. This review article will explore the current and emerging pharmacological and medical device treatments for hyperhidrosis and provide a framework for treating patients who suffer with primary forms of hyperhidrosis.

show abstract

Topical local anaesthetic (tetracaine) reduces pain from botulinum toxin injections for axillary hyperhidrosis

Abstract: A helpful tip

Cited by 18 publications

References 7 publications

Botulinum Toxin for Hyperhidrosis

Botulinum Toxin for Hyperhidrosis

Experience with botulinum toxin therapy for axillary hyperhidrosis and comparison to modelled data for endoscopic thoracic sympathectomy – A quality of life and cost effectiveness analysis

Current and Emerging Medical Therapies for Primary Hyperhidrosis

Contact Info

Product

Resources

About